Xeno Biosciences

LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy

LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced today that it has signed a term sheet to acquire selected assets from Xeno Biosciences Inc. The assets include regulatory filings, correspondence, and documentation from FDA and global regulatory interactions, as well as comprehensive CMC data. LPOXY will benefit from ownership of data generated in Xeno's Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient shared by Xeno's...
Read more...

Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity

Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today initiation of Phase 1b clinical study which is designed to provide proof-of-concept weight loss results, along with safety and tolerability, using an optimized formulation of the drug candidate XEN-101, in obese adults. The trial is expected to have top line results by the end of the year. The Phase 1b study is a double blinded, randomized, placebo...
Read more...

Xeno Biosciences Announces New CEO and Financing

Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024. This financing of $1.15M will fund a Phase 1b trial of the company’s lead compound, Xen-101, in obese individuals. The trial is expected to have top line results by the end of the year. The new...
Read more...

Boston Harbor Angels leads Xeno Biosciences $7.25M Series A Round

Somerville, MA, Aug 8, 2021 – Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today the completion of the Company’s Series A financing, which raised $7.25M in a private round. The investment round was led by Boston Harbor Angels and was joined by a syndicate of individuals and groups including Clinical Research Ventures, Maine Angels, Bangor Angels, Dirigo Angels, Santa Barbara Angels, Beacon Angels, SideCar Angels, NOLA...
Read more...